Insights

Diagnostic Partnerships OncXerna has partnerships with QIAGEN and Exact Sciences to develop and commercialize companion diagnostics for navicixizumab. This creates potential opportunities for diagnostic development, assay integration, laboratory services, and partnership support.

Precision Platform Its Xerna platform combines RNA expression biomarkers with AI to help match patients to oncology therapies. Vendors offering AI, bioinformatics, genomic data analysis, cloud infrastructure, or clinical decision support may find a strong fit.

Clinical Development Navicixizumab is being studied in ovarian, triple negative breast, and colorectal cancers, while bavituximab is in Phase 2 trials. Clinical research organizations, trial recruitment providers, site networks, and clinical data vendors could support ongoing development.

Funded Growth With reported funding of $127 million and a small team of 11 to 50 employees, OncXerna may need external expertise and scalable services rather than large in house teams. Specialized vendors in regulatory affairs, manufacturing, quality, and commercialization may be relevant prospects.

Leadership Access The appointment of CFO Evan Ballantyne signals a dedicated finance function at a lean, clinical stage biotech. Business development teams can tailor outreach around budget visibility, operational efficiency, and partnerships that advance clinical programs or prepare candidates for commercialization.

Similar companies to OncXerna Therapeutics

OncXerna Therapeutics Tech Stack

OncXerna Therapeutics uses 8 technology products and services including cdnjs, WordPress, CookieYes, and more. Explore OncXerna Therapeutics's tech stack below.

  • cdnjs
    Content Delivery Network
  • Content Management System
  • Cookie Compliance
  • MySQL
    Database
  • E-commerce
  • TweenMax
    Javascript Frameworks
  • Lodash
    Javascript Libraries
  • Platform As A Service

Media & News

OncXerna Therapeutics's Email Address Formats

OncXerna Therapeutics uses at least 2 email formats:
OncXerna Therapeutics Email FormatsExamplePercentage
FLast@oncxerna.comJDoe@oncxerna.com
64%
Last@oncxerna.comDoe@oncxerna.com
36%

Frequently Asked Questions

What is OncXerna Therapeutics's phone number?

Minus sign iconPlus sign icon
You can contact OncXerna Therapeutics's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is OncXerna Therapeutics's official website and social media links?

Minus sign iconPlus sign icon
OncXerna Therapeutics's official website is oncxerna.com and has social profiles on LinkedIn.

How much revenue does OncXerna Therapeutics generate?

Minus sign iconPlus sign icon
As of July 2026, OncXerna Therapeutics's annual revenue is estimated to be $1M - $10M.

What is OncXerna Therapeutics's SIC code and NAICS code?

Minus sign iconPlus sign icon
OncXerna Therapeutics's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does OncXerna Therapeutics have currently?

Minus sign iconPlus sign icon
As of July 2026, OncXerna Therapeutics has approximately 11 employees across 3 continents, including North America, Asia and Europe. Key team members include Chief Financial Officer: C. E. and Vice President Clinical Development: K. C. Explore OncXerna Therapeutics's employee directory with LeadIQ.

What industry does OncXerna Therapeutics belong to?

Minus sign iconPlus sign icon
OncXerna Therapeutics operates in the Biotechnology Research industry.

What technology does OncXerna Therapeutics use?

Minus sign iconPlus sign icon
OncXerna Therapeutics's tech stack includes cdnjs, WordPress, CookieYes, MySQL, Shopify, TweenMax, Lodash and WP Engine.

What is OncXerna Therapeutics's email format?

Minus sign iconPlus sign icon
OncXerna Therapeutics's email format typically follows the pattern of FLast@oncxerna.com. Find more OncXerna Therapeutics email formats with LeadIQ.

How much funding has OncXerna Therapeutics raised to date?

Minus sign iconPlus sign icon
As of July 2026, OncXerna Therapeutics has raised $127M in funding. The last funding round occurred on Mar 03, 2022 for $30M.

When was OncXerna Therapeutics founded?

Minus sign iconPlus sign icon
OncXerna Therapeutics was founded in 2018.
OncXerna Therapeutics logo

OncXerna Therapeutics

Biotechnology ResearchMassachusetts, United States11-50 Employees

OncXerna Therapeutics is a clinical-stage biotechnology company focused on precision medicine for oncology. It develops therapies for solid tumors and utilizes an RNA expression-based biomarker approach to match a patient’s tumor with the most appropriate drug, aiming to accelerate development, regulatory approval, and eventual commercialization. The company’s lead candidate, navicixizumab, targets DLL4 and VEGF and is being studied in ovarian cancer, triple-negative breast cancer, and colorectal cancer, while another candidate, bavituximab, is in Phase 2 trials to counter tumor immune suppression. These programs are supported by ongoing collaborations and a broader platform that integrates biomarker data with clinical development expertise to inform treatment strategies.

Section iconCompany Overview

Phone number
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2018
Employees
11-50

Section iconFunding & Financials

  • $127M

    OncXerna Therapeutics has raised a total of $127M of funding over 3 rounds. Their latest funding round was raised on Mar 03, 2022 in the amount of $30M as a Venture Round.

  • $1M - $10M

    OncXerna Therapeutics's revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.